Perbak Capital Partners LLP Vaxcyte, Inc. Transaction History
Perbak Capital Partners LLP
- $568 Billion
- Q3 2025
A detailed history of Perbak Capital Partners LLP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Perbak Capital Partners LLP holds 40,931 shares of PCVX stock, worth $1.98 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
40,931
Previous 26,419
54.93%
Holding current value
$1.98 Million
Previous $859 Million
71.66%
% of portfolio
0.26%
Previous 0.19%
Shares
2 transactions
Others Institutions Holding PCVX
# of Institutions
319Shares Held
133MCall Options Held
408KPut Options Held
116K-
Janus Henderson Group PLC London, X013.1MShares$633 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$596 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$578 Million7.4% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$480 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.32MShares$402 Million0.18% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.87B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...